REDCURE Registry for Chronic Kidney Disease (CKD) Anemia
REDCURE
Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)
1 other identifier
observational
384
0 countries
N/A
Brief Summary
A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 8, 2026
CompletedFirst Posted
Study publicly available on registry
January 16, 2026
CompletedStudy Start
First participant enrolled
January 30, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2027
January 20, 2026
January 1, 2026
1 year
January 8, 2026
January 15, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum hemoglobin levels
Hemoglobin response to therapy
3 months
Secondary Outcomes (1)
Frequency of MACE ( Major Adverse Cardiovascular Events)
3 months
Study Arms (1)
Daprodustat arm for CKD anemia patients
Daprodustat arm for CKD anemia patients
Interventions
Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug
Eligibility Criteria
patients with Chronic Kidney Disease (CKD) anemia requiring anemia treatment
You may qualify if:
- Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
- Patients on hemodialysis (HD) or peritoneal dialysis (PD)
- Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent
You may not qualify if:
- Acute Kidney Injury (AKI) without underlying chronicity
- Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
- Refusal or inability to provide consent
- Current enrollment in an interventional trial that restricts real-world data collection
- Life expectancy \< 3 months, where follow-up is not feasible
- Known contraindications to Daprodustat as per local prescribing information
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Interventions
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 8, 2026
First Posted
January 16, 2026
Study Start
January 30, 2026
Primary Completion (Estimated)
January 30, 2027
Study Completion (Estimated)
May 31, 2027
Last Updated
January 20, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share